Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02408432 · ClinicalTrials.gov registry record · Phase 1

Bone Marrow Derived Mesenchymal Stem Cells in Improving Heart Function in Patients With Heart Failure Caused by Anthracyclines

A Phase 1 study of Heart Failure and Cardiomyopathy, sponsored by M.D. Anderson Cancer Center.

Completed
Registry status
Phase 1
Development phase
7
Enrollment target
1
Study location

NCT02408432 is a Phase 1 study of Heart Failure and Cardiomyopathy that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 7 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02408432, a Phase 1 study of Heart Failure and Cardiomyopathy, has completed, sponsored by M.D. Anderson Cancer Center.

COMPLETED
Registry status
Phase 1
Development phase
7 participants
Enrollment target
1
Study location

Study Summary

This randomized pilot phase I trial studies the side effects and best method of delivery of bone marrow derived mesenchymal stem cells (MSCs) in improving heart function in patients with heart failure caused by anthracyclines (a type of chemotherapy drug used in cancer treatment). MSCs are a type of stem cell that can be removed from bone marrow and grown into many different cell types that can be used to treat cancer and other diseases, such as heart failure. Bone marrow derived MSCs may promote heart muscle cells repair and lead to reverse remodeling and ultimately improve heart function and decrease morbidity and mortality from progression to advanced heart failure.

Conditions Studied

Heart Failure Cardiomyopathy

Interventions

  • OTHER Standard of Care
  • OTHER Laboratory Biomarker Analysis
  • DRUG Mesenchymal Stem Cell Transplantation

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 7 participants
Start Date 2016-01-11
Est. Completion 2021-12-08
Phase Phase 1

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02408432

The ClinicalTrials.gov registry entry for NCT02408432 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (100% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Heart Failure appearing as the primary indexed condition, and to 3 interventions - of which Standard of Care is the first listed.

NCT02408432 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT02408432 about?

NCT02408432 is a clinical study titled "Bone Marrow Derived Mesenchymal Stem Cells in Improving Heart Function in Patients With Heart Failure Caused by Anthracyclines". This randomized pilot phase I trial studies the side effects and best method of delivery of bone marrow derived mesenchymal stem cells (MSCs) in improving heart function in patients with heart failure caused by anthracyclines (a type of chemotherapy drug used in cancer treatment). MSCs are a type of...

What is the current status of trial NCT02408432?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2016-01-11. Estimated completion is 2021-12-08.

What conditions does trial NCT02408432 study?

This clinical trial studies the following conditions: Heart Failure, Cardiomyopathy.

What interventions are being tested in trial NCT02408432?

The interventions under investigation include: Standard of Care (OTHER), Laboratory Biomarker Analysis (OTHER), Mesenchymal Stem Cell Transplantation (DRUG).

Who is sponsoring clinical trial NCT02408432?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02408432 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Heart Failure

All registered trials for this condition

Cardiomyopathy

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.